Further analysis of ADAS-Cog data from the Company's randomized, sham-controlled clinical trial — pr

HOUSTON, TX, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company”

Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-

Gainers ENDRA Life Sciences (NASDAQ:NDRA) shares rose 10.8% to $5.94 during Tuesday's after-mar

Gainers iTonic Holdings (NASDAQ:ITOC) stock increased by 8.1% to $0.3 during Friday's after-mar

Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-marke

Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday'

Dr. Victor Fontenelle Bastos de Lima, an investigator on Nexalin's recently completed Brazilian clin

Accepted abstracts showcase Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinica

Study using Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform demonstrated rapid, large-m

Newly issued U.S. patent expected to provide core intellectual property protection through 2042, fur

U.S. House Appropriations Committee report language directs VA to support additional research evalua

Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture

Publication reports statistically significant improvement in sleep quality following treatment with

160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submi

HOUSTON, TX, April 15, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company

ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on A

IDEAYA Biosciences shares (NASDAQ: IDYA) jumped 18% in pre-market trading after announcing topline

BMC Psychiatry publication reports statistically significant reductions in self-injury behaviors and

Nexalin Technology (NASDAQ: NXL - Get Free Report) and Algorhythm (NASDAQ: RIME - Get Free Report) a

Nexalin Technology, Inc. (NASDAQ: NXL - Get Free Report) saw a significant decline in short interest

150-Patient, Triple-Blinded, Sham-Controlled Study Designed to be Executed in Collaboration with Lin

Nexalin Participates in & Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulat

New digital health platform being launched in partnership with UCSD allows remote physician-monitore

Nexalin launched its AI-powered NeuroCare virtual clinic with UC San Diego, enabling at-home brain t

HOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company”